Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05965180

Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe

In this project, we will integrate the Photoacoustic (PA) technology into a prostate biopsy procedure through a fine needle probe. The needle probe will be in the shape of a biopsy needle and compatible with the needle insertion mechanism in the transrectal ultrasound (TRUS) probe. When inserted into the prostate, the fine needle PA probe will assess the histological information in its surrounding tissue without any tissue extraction. The needle probe has been tested in prostate tissue samples and whole human prostates ex vivo.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year–80 year

Sex eligibility

Male

Study type

Observational

Primary location

University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States

Location status: Recruiting

Location contact

Cancer AnswerLine

CONTACT

[email protected]

800-865-1125

Guan Xu, Phd

PRINCIPAL_INVESTIGATOR

About this study

14AUG2024- enrollment was increased to 50 subjects

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1) Planned prostate biopsy as part of routine clinical care
  • 2) > 40 and <80 years old

Exclusion criteria

  • 1) Known history of bleeding disorders or
  • 2) Patients taking anticoagulants, no matter doses or washout time
  • 3) Known allergy to silicone material
  • 4) Unable to provide informed consent
  • 5) Either the surgeon or the patient do not think the patient will not be able to complete all parts of the study, the patient will be excluded
  • 6) Involved in other investigational studies.

Treatment and study plan

Fine Needle Photoacoustic Probe

Device

Fine Needle Photoacoustic Probe guided by the standard biopsy system without tissue core extraction

Primary outcomes

  1. Demonstration of reliable measurements

    Time frame: day 1

    The primary aim of this study is to demonstrate that our fine needle PA probe can acquire reliable measurements of prostate glands. This will be indicated by a signal-to-noise ratio of the measurements that is larger than one.

    We will calculate the signal to noise ratio of the signals as the peak-to-peak signal magnitude over the amplitude of the system background signal. The technical failure is that we will not be able to achieve measurements with signal-to-noise ratios larger than 1 in 10% of the measurements. We will have a futility analysis after first 5 patients are completed (thus 10 measurements). If of those 10 measurements, 2 have a SNR less 1, then the study will be stopped as it is unlikely to meet its 90% target.

Secondary outcomes

  1. Determining the ability to observe differences between benign and cancerous regions

    Time frame: day 1

    The secondary aim of this study is documenting our ability to observe differences between the PASA linear slope values derived from benign and cancerous regions, i.e., to detect the difference of 0.05 of 0.19, 0.17, 0.14, 0.20 dB/MHz between the means of the linear slopes in benign and cancerous regions at the wavelengths of 1220 nm, 1370 nm, 800 nm and 266 nm, respectively.

    We will aim at differentiating the measurements in benign and cancerous regions at specific wavelengths. We have a null hypothesis for each wavelength that at this specific wavelength, our measurement cannot differentiate the benign and cancerous regions. We will test the hypothesis with paired t-tests.

Study contacts

Contact information is provided by the study sponsor or research team.

Cancer AnswerLine

CONTACT

[email protected]

1-800-865-1125

Sponsors and collaborators

Lead sponsor

University of Michigan Rogel Cancer Center

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jul 28, 2023
Registry last updated
Nov 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.